Acute Pain News and Research RSS Feed - Acute Pain News and Research

Markovian models show promise for describing postoperative pain trajectories

Markovian models show promise for describing postoperative pain trajectories

Markovian models show promise for describing postoperative pain states and, eventually, may help guide clinical decisions, a new study found. [More]

AAPM announces 2015 Presidential Commendations for exceptional service in Pain Medicine

The American Academy of Pain Medicine is pleased to announce its 2015 Presidential Commendations for exceptional service to the Academy and/or the field of Pain Medicine. [More]
AAPM announces recipients of 2015 Pain Medicine Fellowship Excellence Award

AAPM announces recipients of 2015 Pain Medicine Fellowship Excellence Award

The American Academy of Pain Medicine is pleased to announce its 2015 Pain Medicine Fellowship Excellence Award Recipients in recognition of a Pain Medicine Fellowship Program that provides an exceptional learning experience to its fellows, preparing them to deliver the highest standard of care to patients with pain. [More]
Study investigates effects of antidepressant treatment in pain catastrophizing patients

Study investigates effects of antidepressant treatment in pain catastrophizing patients

A select population of patients having surgery experience what is called pain catastrophizing - an irrational thought process that leads a patient to perceive pain as worse than it actually is. Antidepressant medications reduce negative mood and might change this way of thinking, but according to a study published in the April edition of Anesthesiology, the official medical journal of the American Society of Anesthesiologists, that may not be the case, at least for acute pain. [More]
AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported dosing of the first patient in the pivotal Phase 3 study of ARX-04. [More]
New poll finds pain as key correlates of shorter sleep durations, worse sleep quality

New poll finds pain as key correlates of shorter sleep durations, worse sleep quality

A new poll by the National Sleep Foundation finds that pain is a key factor in the gap between the amount of sleep Americans say they need and the amount they're getting - an average 42 minute sleep debt for those with chronic pain and 14 minutes for those who've suffered from acute pain in the past week. [More]
ANI Pharmaceuticals launches Etodolac 300mg oral capsules

ANI Pharmaceuticals launches Etodolac 300mg oral capsules

ANI Pharmaceuticals, Inc. today announced the launch of Etodolac 300mg oral capsules, indicated for use in the management of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and acute pain. [More]
Mylan announces U.S. launch of Celecoxib Capsules

Mylan announces U.S. launch of Celecoxib Capsules

Mylan Inc. today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. [More]
AcelRx Pharmaceuticals' Zalviso device gets CE Mark approval

AcelRx Pharmaceuticals' Zalviso device gets CE Mark approval

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device. [More]
National Spine & Pain Centers opens new pain management center in Cumberland, Maryland

National Spine & Pain Centers opens new pain management center in Cumberland, Maryland

Over 100 million adults suffer from chronic pain and about half of those suffer from this pain daily. Chronic and acute pain dramatically impacts quality of life. The specialty of pain management is born to fulfill the need for non-surgical, interventional solutions and medication management to treat all types of pain. [More]
Alliance for Balanced Pain Management established to support appropriate access to pain management

Alliance for Balanced Pain Management established to support appropriate access to pain management

A diverse collective of health care advocacy groups, patient organizations, industry representatives and other stakeholders today announced they have established the Alliance for Balanced Pain Management (AfBPM) to support appropriate access to integrated pain management and responsible use of prescription pain medicines with an aim to reduce abuse. [More]
Pre-treatment pain intensity predicts survival of patients with head and neck cancer

Pre-treatment pain intensity predicts survival of patients with head and neck cancer

Pre-treatment pain intensity is an independent survival predictor for patients with head and neck cancer, according to new research published in The Journal of Pain, the peer-reviewed publication of the American Pain Society. [More]
Protein Sciences releases Flublok influenza vaccine for the 2014/2015 season

Protein Sciences releases Flublok influenza vaccine for the 2014/2015 season

Protein Sciences Corporation, manufacturer of the revolutionary Flublok influenza vaccine, announced today that doses of the vaccine have been released and are now available for shipment. [More]
AcelRx plans for resubmission of Zalviso NDA

AcelRx plans for resubmission of Zalviso NDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update on the plans for the resubmission of the Company's New Drug Application (NDA) for Zalviso (sufentanil sublingual tablet system). [More]
Epidurals and reduced postpartum depression: an interview with Dr. Zakowski

Epidurals and reduced postpartum depression: an interview with Dr. Zakowski

The “maternity blues”, which resolve within 10 days of giving birth, occurs in up to 80% of new moms. A major depressive episode, by Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria, is defined as having at least a 2-week period of persistent depressed mood ... [More]

Studies support clinical use of antidepressants for treatment of postoperative pain

Antidepressants are known to provide effective pain relief for various chronic pain conditions; however, the jury is still out on their use in treating the millions of patients who suffer from acute or chronic pain following surgery. [More]
Regional anesthesia technique allows majority of patients to go home within hours of surgery

Regional anesthesia technique allows majority of patients to go home within hours of surgery

A recent study of an ultrasound-guided regional anesthesia technique, called femoral nerve block, shows that it leads to less opioid use and allows the majority of patients to go home within hours of surgery. [More]
FDA issues Complete Response Letter for AcelRx's Zalviso NDA

FDA issues Complete Response Letter for AcelRx's Zalviso NDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso (sufentanil sublingual tablet system). [More]

Phase 2 dose-ranging study of AYX1 for prevention of post-surgical pain

Adynxx, developer of a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in ADYX-003, a Phase 2 dose-ranging study of AYX1, an investigational drug candidate for the prevention of post-surgical pain. [More]
Grunenthal Group submits Marketing Authorization Application to EMA for ZALVISO

Grunenthal Group submits Marketing Authorization Application to EMA for ZALVISO

AcelRx Pharmaceuticals, Inc. and Grunenthal Group announced today that Grunenthal has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO for the management of moderate to severe acute pain in adult patients in a medically supervised environment. [More]
Advertisement
Advertisement